Geode Capital Management
RARX

Geode Capital Management’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Geode Capital Management’s Portfolio RARX Stock Details RARX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-513,937
Closed -$24.7M – 4201
2020
Q1 		$24.7M Sell
513,937
-11,647
-2% -$542K 0.01% 1153
2019
Q4 		$24.7M Buy
525,584
+10,207
+2% +$451K 0.01% 1418
2019
Q3 		$12.2M Buy
515,377
+68,389
+15% +$2.03M ﹤0.01% 1804
2019
Q2 		$13.4M Buy
446,988
+75,500
+20% +$1.73M ﹤0.01% 1737
2019
Q1 		$8.32M Buy
371,488
+63,974
+21% +$1.38M ﹤0.01% 2021
2018
Q4 		$5.6M Buy
307,514
+123,539
+67% +$1.94M ﹤0.01% 2151
2018
Q3 		$3.33M Buy
183,975
+38,510
+26% +$456K ﹤0.01% 2615
2018
Q2 		$1.45M Buy
145,465
+31,428
+28% +$217K ﹤0.01% 3025
2018
Q1 		$605K Buy
114,037
+29,818
+35% +$213K ﹤0.01% 3335
2017
Q4 		$715K Buy
84,219
+7,435
+10% +$91.4K ﹤0.01% 3223
2017
Q3 		$1.12M Buy
76,784
+1,647
+2% +$24.9K ﹤0.01% 3076
2017
Q2 		$1.41M Buy
75,137
+4,274
+6% +$96.4K ﹤0.01% 2927
2017
Q1 		$1.51M Buy
70,863
+5,522
+8% +$106K ﹤0.01% 2802
2016
Q4 		$992K Buy
+65,341
New +$888K ﹤0.01% 2994

Other funds holding RARX

Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Geode Capital Management's RARX Position: Q2 2020 in Review

Geode Capital Management sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 513,937 shares — an estimated $24.7M sold.

Geode Capital Management first reported a position in RARX in Q4 2016 and held it in 14 quarters. The position peaked at $24.7M in Q1 2020. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

  • Geode Capital Management reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Geode Capital Management sold 513,937 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $24.7M.
  • Geode Capital Management first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 14 quarters.
  • Geode Capital Management's Ra Pharmaceuticals, Inc. Common Stock position peaked at $24.7M in Q1 2020.
  • 1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Geode Capital Management's 13F filing for Q2 2020, filed 13 Aug 2020.